BofA raised the firm’s price target on Ascendis Pharma (ASND) to $216 from $201 and keeps a Buy rating on the shares. The firm notes the company ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for TransCon ® CNP (navepegritide) for the treatment of children with achondroplasia, a rare ...

Ascendis Pharma operates in a competitive environment, particularly in the achondroplasia market where companies like BioMarin (NASDAQ:BMRN) have established products. However, analysts believe that ...

As Ascendis navigates the complex pharmaceutical market, investors will be closely watching the performance of Yorvipath and the development of TransCon CNP as key indicators of the company’s ...